Clinical Trial Update: A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread [Phase 1]

View source ↗

Summary

Phase 1 study update for BPX-601 CAR T-Cell Therapy in adults with prostate cancer that has recurred, is treatment-resistant, and metastasized; status: not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BPX-601 CAR T-Cell Therapy

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Prostate Cancer | Phase 1 | Status: NOT_YET_RECRUITING